Cellular immunity in inflammatory autoimmune neuropathies

Revue Neurologique

Volumn 158, Issue 12 II, 2002, Pages

  Maurer M ^a   Toyka, K V ^a   Gold, R ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; CONFERENCE PAPER; CYTOKINE PRODUCTION; DEMYELINATING DISEASE; DEMYELINATION; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFLAMMATION; MACROPHAGE ACTIVATION; NEURITIS; NEUROPATHY; PERIPHERAL NERVE; PLASMAPHERESIS; POLYNEUROPATHY; REGULATORY MECHANISM; T LYMPHOCYTE ACTIVATION; APOPTOSIS; IMMUNOLOGY; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; PATHOLOGY; PHYSIOLOGY; POLYRADICULONEUROPATHY; REVIEW; SCHWANN CELL; T LYMPHOCYTE;

CYTOKINE; INTERCELLULAR ADHESION MOLECULE 1; VASCULAR CELL ADHESION MOLECULE 1;

APOPTOSIS; CYTOKINES; GUILLAIN-BARRE SYNDROME; INTERCELLULAR ADHESION MOLECULE-1; MACROPHAGES; MAJOR HISTOCOMPATIBILITY COMPLEX; PERIPHERAL NERVES; POLYRADICULONEUROPATHY; SCHWANN CELLS; T-LYMPHOCYTES; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0036916670     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (97)

1. Abromson-Leeman S, Bronson R, Dorf ME. (1995). Experimental autoimmune peripheral neuritis induced in BALB/c mice by myelin basic protein-specific T-cell clones. J Exp Med, 182: 587-592.
2. Archelos JJ, Mäurer M, Jung S, Toyka KV, Hartung HP. (1993). Suppression of experimental allergic neuritis by an antibody to the intracellular adhesion molecule ICAM-1. Brain, 116: 1043-1058.
3. Archelos JJ, Mäurer M, Jung S, et al. (1994). Inhibition of experimental autoimmune neuritis by an antibody to the lymphocyte function-associated antigen-1. Lab Invest, 70: 667-675.
4. Archelos JJ, Fortwangler T, Hartung HP. (1997). Attenuation of experimental autoimmune neuritis in the Lewis rat by treatment with an antibody to L-selectin. Neurosci Lett, 235: 9-12.
5. Archelos JJ, Jung S, Rinner W, Lassmann H, Miyasaka M, Hartung HP. (1998). Role of the leukocyte-adhesion molecule L-selectin in experimental autoimmune encephalomyelitis. J Neurol Sci, 159: 127-134.
6. Armati PJ, Pollard JD, Gatenby P. (1990). Rat and human Schwann cells in vitro can synthesize and express MHC molecules. Muscle Nerve, 13: 106-116.
7. H1-type immune responses. Clin Immunol Immunopathol, 83:117-126.
8. Ballin RH, Thomas PK. (1969). Electron microscope observations on demyelination and remyelination in experimental allergic neuritis. I. Demyelination. J Neurol Sci, 8: 1-18.
9. Barnett LA, Fujinami RS. (1992) Molecular mimicry: A mechanism for autoimmune injury. FASEB J, 6: 840-844.
10. Bauer J, Bradl M, Hickley WF, et al. (1998). T-cell apoptosis in inflammatory brain lesions: Destruction of T-cells does not depend on antigen recognition [see comments]. Am J Pathol, 153: 715-724.
11. Ben Smith A, Gaston JS, Barber PC, Winer JB. (1996). Isolation and characterisation of T lymphocytes from sural nerve biopsies in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry, 61: 362-368.
12. Bergsteinsdottir K, Kingston A, Jessen KR. (1992). Rat Schwann cells can be induced to express major histocompatibility complex class II molecules in vivo. J Neurocytol, 21: 382-390.
13. Brosnan JV, Craggs RI, King RH, Thomas PK. (1987). Reduced susceptibility of T-cell-deficient rats to induction of experimental allergic neuritis. J Neuroimmunol, 14: 267-282.
14. Brostoff SW, Levit S, Powers JM. (1977). Induction of experimental allergic neuritis with a peptide from myelin P2 basic protein. Nature, 268: 752-753.
15. Buchwald B, Toyka KV, Zielasek J, Weishaupt A, Schweiger S, Dudel J. (1998). Neuromuscular blockade by IgG antibodies from patients with Guillain-Barré syndrome: A macro-patch-clamp study. Ann Neurol, 44: 913-922.
16. Constable AL, Armati PJ, Toyka KV, Hartung HP. (1994). Production of prostanoids by Lewis rat Schwann cells in vitro. Brain Res, 635: 75-80.
17. Cooper JC, Ben Smith A, Savage CO, Winer JB. (2000). Unusual T-cell receptor phenotype V gene usage of gamma delta T-cells in a line derived from the peripheral nerve of a patient with Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry, 69: 522-524.
18. Craggs RI, King RH, Thomas PK. (1984). The effect of suppression of macrophage activity on the development of experimental allergic neuritis. Acta Neuropathol (Berl), 62: 316-323.
19. Dustin ML, Shaw AS. (1999). Costimulation: Building an immunological synapse. Science, 283: 649-650.
20. Enders U, Lobb R, Pepinsky RB, Hartung HP, Toyka KV, Gold R. (1998). The role of the very late antigen-4 (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) in the pathogenesis of experimental autoimmune neuritis (EAN) of the Lewis rat. Brain, 121: 1257-1266.
21. Fujioka T, Kolson DL, Rostami AM. (1999). Chemokines and peripheral nerve demyelination. J Neurovirol, 5: 27-31.
22. Gabriel CM, Hughes RAC, Moore SE, Smith KJ, Walsh FS. (1998). Induction of experimental autoimmune neuritis with peripheral myelin protein-22. Brain, 121: 1895-1902.
23. Gold R, Toyka KV, Hartung HP. (1995). Synergistic effect of gamma-IFN and TNF-α on expression of immune molecules and antigen presentation by Schwann cells. Cell Immunol, 165: 65-70.
24. Gold R, Pepinsky RB, Zettl UK, Toyka KV, Hartung HR (1996). Lipocortin-1 (annexin-1) suppresses activation of autoimmune T-cell lines in the Lewis rat. J Neuroimmunol, 69: 157-164.
25. Gold R, Archelos JJ, Hartung HP. (1999). Mechanisms of immune regulation in the peripheral nervous system. Brain Pathol, 9: 343-360.
26. Gold R, Hartung HP, Toyka KV. (2000). Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today, 6:88-91
27. Griffin JW, Li CY, Ho TW, et al. (1996). Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases - Reply. Brain, 119: 677-680.
28. Guillain-Barré Syndrome Steroid Trial Group. (1993). Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet, 341: 586-590.
29. Hadden RD, Karch H, Hartung HP, et al. (2001). Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology, 56: 758-765.
30. Hafer-Macko CE, Sheikh KA, Li CY, et al. (1996a). Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Annals of Neurology, 39: 627-637.
31. Hafer-Macko CE, Sheikh KA, Li CY, et al. (1996b). Acute motor axonal neuropathy: An antibody-mediated attack on axolemma. Ann Neurol, 40: 635-644.
32. Hartung HP, Heininger K, Schäfer B, Toyka KV. (1988a). Substance P and astrocytes: Stimulation of the cyclooxygenase pathway of arachidonic acid metabolism. FASEB J, 2: 48-51.
33. Hartung HP, Schäfer B, Heininger K, Toyka KV. (1988b). Suppression of experimental autoimmune neuritis by the oxygen radical scavengers superoxide dismutase and catalase. Ann Neurol, 23: 453-460.
34. Hartung HP, Schaf̈er B, Diamantstein T, Fierz W, Heininger K, Toyka KV. (1989). Suppression of P2-T-cell line-mediated experimental autoimmune neuritis by interleukin-2 receptor targeted monoclonal antibody ART 18. Brain Res, 489: 120-128.
35. Hartung HP, Toyka KV. (1990). T-cell and macrophage activation in experimental autoimmune neuritis and Guillain-Barré syndrome. Ann Neurol, 27: S57-S63.
36. Hartung HP, Reiners K, Schmidt B, Stoll G, Toyka KV. (1991). Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: Comparison with other neurological diseases of presumed immunopathogenesis. Ann Neurol, 30: 48-53.
37. Hartung HP. (1993). Immune-mediated demyelination. Ann Neurol, 33: 563-567.
38. Hartung HP, Van Der Meche FG, Pollard JD. (1998). Guillain-Barré syndrome, CIDP and other chronic immune-mediated neuropathies [editorial]. Curr Opin Neurol, 11: 497-513.
39. Hartung HP, Kieseier BC, Kiefer R. (2001). Progress in Guillain-Barré syndrome. Curr Opin Neurol, 14: 597-604.
40. Heininger K, Stoll G, Linington C, Toyka KV, Wekerle H. (1986). Conduction failure and nerve conduction slowing in experimental allergic neuritis induced by P2-specific T-cell lines. Ann Neurol, 19: 44-49.
41. Heininger K, Schäfer B, Hartung HP, Fierz W, Linington C, Toyka KV. (1988). The role of macrophages in experimental autoimmune neuritis induced by a P2-specific T-cell line. Ann Neurol, 23: 326-331.
42. Ho TW, McKhann M, Griffin JW. (1998). Human autoimmune neuropathies. Ann Rev Neurosci, 21: 187-226.
43. Hughes PM, Wells GMA, Clements JM, et al. (1998). Matrix metalloproteinase expression during experimental autoimmune neuritis. Brain, 121: 481-494.
44. Hughes RA, Hadden RD, Gregson NA, Smith KJ. (1999). Pathogenesis of Guillain-Barré syndrome. J Neuroimmunol, 100: 74-97.
45. Jung S, Kramer S, Schluesener HJ, Hünig T, Toyka K, Hartung HP. (1992). Prevention and therapy of experimental autoimmune neuritis by an antibody against T-cell receptors-alpha/beta. J Immunol, 148: 3768-3775.
46. Jung S, Huitinga I, Schmidt B, et al. (1993). Selective elimination of macrophages by dichlormethylene diphosphonate-containing liposomes suppresses experimental autoimmune neuritis. J Neurol Sci, 119: 195-202.
47. Khalili Shirazi A, Hughes RA, Brostoff SW, Linington C, Gregson N. (1992). T-cell responses to myelin proteins in Guillain-Barré syndrome. J Neurol Sci, 111: 200-203.
48. Kiefer R, Funa K, Schweitzer T, et al. (1996). Transforming growth factor beta1 in experimental autoimmune neuritis - Cellular localization and time course. Am J Pathol, 148: 211-223.
49. Kiefer R, Kieseier BC, Brück W, Hartung HP, Toyka KV. (1998). Macrophage differentiation antigens in acute and chronic autoimmune polyneuropathies. Brain, 121: 469-479.
50. Kiefer R, Kieseier BC, Stoll G, Hartung H. (2001). The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol, 64: 109-127.
51. Kieseier BC, Clements JM, Pischel HB, et al. (1998). Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barré syndrome. Ann Neurol, 43: 427-434.
52. Koski CL. (1990). Characterization of complement-fixing antibodies to peripheral nerve myelin in Guillain-Barré syndrome. Ann Neurol, 27: 44-47.
53. Koski CL, Estep AE, Sawant-Mane S, Shin ML, Highbarger L, Hansch GM. (1996). Complement regulatory molecules on human myelin and glial cells: Differential expression affects the deposition of activated complement proteins. J Neurochem, 66: 303-312.
54. Lampert PW. (1969). Mechanism of demyelination in experimental allergic neuritis. Electron microscopic studies. Lab Invest, 20: 127-138.
55. Liefner M, Maruschak B, Brock W. (1998). Concentration-dependent effects of pentoxifylline on migration and myelin phagocytosis by macrophages. J Neuroimmunol, 89: 97-103.
56. Linington C, Izumo S, Suzuki M, Uyemura K, Meyermann R, Wekerle H. (1984). A permanent rat T-cell line that mediates experimental allergic neuritis in the Lewis rat in vivo. J Immunol, 133: 1946-1950.
57. Linington C, Mann A, Izumo S, et al. (1986). Induction of experimental allergic neuritis in the BN rat: P2 protein-specific T-cells overcome resistance to actively induced disease. J Immunol, 137: 3826-3831.
58. Linington C, Lassmann H, Ozawa K, Kosin S, Mongan L. (1992). Cell adhesion molecules of the immunoglobulin supergene family as tissue-specific autoantigens: Induction of experimental allergic neuritis (EAN) by PO protein-specific T-cell lines. Eur J Immunol, 22: 1813-1817.
59. Morfin R, Young J, Corpechot C, Egestad B, Sjovall J, Baulieu EE. (1992). Neurosteroids: Pregnenolone in human sciatic nerves. Proc Natl Acad Sci USA, 89: 6790-6793.
60. Nagata S, Golstein P. (1995). The Fas death factor. Science, 267: 1449-1455.
61. Oka N, Akiguchi I, Kawasaki T, Mizutani K, Satoi H, Kimura J. (1998). Tumor necrosis factor-α in peripheral nerve lesions. Acta Neuropathol (Berl), 95: 57-62.
62. Olee T, Powell HC, Brostoff SW. (1990). New minimum length requirement for a T-cell epitope for experimental allergic neuritis. J Neuroimmunol, 27: 187-190.
63. Oono T, Fukui Y, Masuko S, et al. (2002). Organ-specific autoimmunity in mice whose T-cell repertoire is shaped by a single antigenic peptide. J Clin Invest, 108: 1589-1596.
64. Pollard JD, Baverstock H, McLeod JG. (1987). Class II antigen expression and inflammatory cells in the Guillain-Barré syndrome. Ann Neurol, 21: 337-341.
65. Prineas JW. (1994). Pathology of inflammatory demyelinating neuropathies. Baillieres. Clin Neurol, 3: 1-24.
66. Ransohoff RM. (1999). Mechanisms of inflammation in MS tissue: Adhesion molecules and chemokines. J Neuroimmunol, 98: 57-68.
67. Redford EJ, Hall SM, Smith KJ. (1995). Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor. Brain, 118: 869-878.
68. Salomon B, Rhee L, Bour-Jordan H, et al. (2001). Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice. J Exp Med, 194: 677-684.
69. Schmidt B, Stoll G, Hartung HP, Heininger K, Schafer B, Toyka KV. (1990). Macrophages but not Schwann cells express la antigen in experimental autoimmune neuritis. Ann Neurol, 28: 70-77.
70. Schmidt B, Toyka KV, Kiefer R, Full J, Hartung HP, Pollard J. (1996). Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve, 19: 474-487.
71. Sharief MK, McLean B, Thompson EJ. (1993). Elevated serum levels of tumor necrosis factor-alpha in Guillain-Barré syndrome. Ann Neurol, 33: 591-596.
72. Smith KJ, Kapoor R, Felts PA. (1999). Demyelination: The role of reactive oxygen and nitrogen species. Brain Pathol, 9: 69-92.
73. Spies JM, Westland KW, Bonner JG, Pollard JD. (1995). Intraneural activated T-cells cause focal breakdown of the bloodnerve barrier. Brain, 118: 857-868.
74. Steinman L. (1996), A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: A tale of smart bombs and the infantry. Proc Natl Acad Sci USA, 93: 2253-2256.
75. Stienekemeier M, Falk K, Rötzschke O, et al. (2001). Vaccination, prevention, and treatment of experimental autoimmune neuritis (EAN) by an oligomerized T-cell epitope. J Exp Med, 98: 13872-13877.
76. Stoll G, Schmidt B, Jander S, Toyka KV, Hartung HP. (1991). Presence of the terminal complement complex (C5b-9) precedes myelin degradation in immune-mediated demyelination of the rat peripheral nervous system. Ann Neurol, 30: 147-155.
77. Stoll G, Jung S, Jander S, Van Der Meide P, Hartung HR (1993). Tumor necrosis factor-α in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. J Neuroimmunol, 45:175-182.
78. Tacke M, Hanke G, Hanke T, Hunig T. (1997). CD28-mediated induction of proliferation in resting T-cells in vitro and in vivo without engagement of the T-cell receptor: Evidence for functionally distinct forms of CD28. Eur J Immunol, 27: 239-247.
79. Taylor WA, Brostoff SW, Hughes RA. (1991). P2 specific lymphocyte transformation in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neurol Sci, 104: 52-55.
80. Toyka KV. (1999). Eighty three years of the Guillain-Barré syndrome: Clinical and immunopathologic aspects, current and future treatments. Rev Neurol, 155: 849-856.
81. Vedeler C, Ulvestad E, Bjorge L, et al. (1994). The expression of CD59 in normal human nervous tissue. Immunology, 82: 542-547.
82. Vriesendorp FJ, Mayer RF, Koski CL. (1991). Kinetics of anti-peripheral nerve myelin antibody in patients with Guillain-Barré syndrome treated and not treated with plasmapheresis. Arch Neurol, 48: 858-861.
83. Vriesendorp FJ, Flynn RE, Malone MR, Pappolla MA. (1998). Systemic complement depletion reduces inflammation and demyelination in adoptive transfer experimental allergic neuritis. Acta Neuropathol, 95: 297-301.
84. Weerth S, Berger T, Lassmann H, Linington C. (1999). Encephalitogenic and neuritogenic T-cell responses to the myelin-associated glycoprotein (MAG) in the Lewis rat. J Neuroimmunol, 95: 157-164.
85. Weishaupt A, Gold R, Gaupp S, Giegerich G, Hartung HP, Toyka KV. (1997). Antigen therapy eliminates T-cell inflammation by apoptosis: Effective treatment of experimental autoimmune neuritis with recombinant myelin protein P2. Proc Natl Acad Sci USA, 94: 1338-1343.
86. Weishaupt A, Gold R, Hartung T, et al. (2000). Role of TNF-α in high-dose antigen therapy in experimental autoimmune neuritis: Inhibition of TNF-α by neutralizing antibodies reduces T-cell apoptosis and prevents liver necrosis. J Neuropathol Exp Neurol, 59: 368-376.
87. Weishaupt A, Brück W, Hartung T, Toyka KV, Gold R. (2001a). Schwann cell apoptosis in experimental autoimmune neuritis of the Lewis rat and the functional role of tumor necrosis factor-alpha. Neurosci Lett, 306: 77-80.
88. Weishaupt A, Schönrock L, Stienekemeier M, Toyka KV, Gold R. (2001b). Glucocorticosteroids modulate antigen-induced T-cell apoptosis in experimental autoimmune neuritis and cause T-cell proliferation in situ. Acta Neuropathol, 102: 75-82.
89. Wekerle H, Schwab M, Linington C, Meyermann R. (1986). Antigen presentation in the peripheral nervous system: Schwann cells present endogenous myelin autoantigens to lymphocytes. Eur J Immunol, 16: 1551-1557.
90. Wohlleben G, Ibrahim S, Schmidt J, Toyka KV, Hartung HP, Gold R. (2000). Regulation of Fas and FasL expression on Schwann cells. Glia, 30: 373-381.
91. Yuki N. (1997). Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni isolated from patients with Guillain-Barré syndrome and Miller Fisher syndrome. J Infect Dis, 176: S150-S153.
92. Zettl UK, Gold R, Toyka KV, Hartung HP. (1995). Intravenous glucocorticosteroid treatment augments apoptosis of inflammatory T-cells in experimental autoimmune neuritis (EAN) of the Lewis rat. J Neuropathol Exp Neurol, 54: 540-547.
93. Zettl UK, Gold R, Toyka KV, Hartung HP. (1996). In situ demonstration of T-cell activation and elimination in the peripheral nervous system during experimental autoimmune neuritis in the Lewis rat. Acta Neuropathol, 91: 360-367.
94. Zettl UK, Mix E, Zielasek J, Stangel M, Hartung HP, Gold R. (1997). Apoptosis of myelin-reactive T-cells induced by reactive oxygen and nitrogen intermediates in vitro. Cell Immunol, 178: 1-8.
95. Zielasek J, Jung S, Gold R, Liew FY, Toyka KV, Hartung HP. (1995). Administration of nitric oxide synthase inhibitors in experimental autoimmune neuritis and experimental autoimmune encephalomyelitis. J Neuroimmunol, 58: 81-88.
96. Zipp F, Krammer PH, Weller M. (1999). Immune (dys)regulation in multiple sclerosis: Role of the CD95/CD95 ligand system. Immunol Today, 20: 550-554.
97. Zou LP, Pelidou SH, Abbas N, et al. (1999). Dynamics of production of MIP-1α, MCP-1 and MIP-2 and potential role of neutralization of these chemokines in the regulation of immune responses during experimental autoimmune neuritis in Lewis rats. J Neuroimmunol, 98:168-175.